Redox signaling by the RNA polymerase III TFIIB-related factor Brf2

Autor: Gouge, Jerome, Satia, K., Guthertz, N., Widya, M., Thompson, A.J., Cousin, P., Dergai, O., Hernandez, N., Vannini, A.

Publikováno v: 'Cell ', vol: 163, pages: 1375-1387 (2015)
Cell
Cell, vol. 163, no. 6, pp. 1375-1387

Summary TFIIB-related factor 2 (Brf2) is a member of the family of TFIIB-like core transcription factors. Brf2 recruits RNA polymerase (Pol) III to type III gene-external promoters, including the U6 spliceosomal RNA and selenocysteine tRNA genes. Fou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7d2ec91dc8432e6237e1834b3cc28ced
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:42911

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Circulating tumor cells shed large extracellular vesicles in capillary-sized bifurcations.

Autor: Vrynas A; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Arfan S; Division of Molecular Pathology, The Institute of Cancer Research; London, SM2 5NG, United Kingdom., Satia K; Cancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom., Bazban-Shotorbani S; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Ashna M; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Zhang A; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Visan D; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Chen A; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom., Carter M; Cancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom.; Medical Oncology, Christie Hospital National Health Service (NHS) Foundation Trust; Manchester, M20 4BX, United Kingdom., Blackhall F; Cancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom.; Medical Oncology, Christie Hospital National Health Service (NHS) Foundation Trust; Manchester, M20 4BX, United Kingdom.; The Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester; Manchester, M13 9PL, United Kingdom., Simpson KL; Cancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom.; SCLC Biology Group, Cancer Research UK Manchester Institute, University of Manchester; Manchester, M20 4BX, United Kingdom., Dive C; Cancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom.; SCLC Biology Group, Cancer Research UK Manchester Institute, University of Manchester; Manchester, M20 4BX, United Kingdom., Huang P; Division of Molecular Pathology, The Institute of Cancer Research; London, SM2 5NG, United Kingdom.; Cancer Research UK Convergence Science Centre; London, SW7 2AZ, United Kingdom., Au SH; Department of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.; Cancer Research UK Convergence Science Centre; London, SW7 2AZ, United Kingdom.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Apr 20. Date of Electronic Publication: 2024 Apr 20.